FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office
Executive Summary
US FDA met more biosimilar user fee program meeting performance goals in FY 2018 compared to prior year but still fell short in scheduling for three of five types of meetings. Office of New Drugs reorganization, once completed, should address some logistical scheduling issues.
You may also be interested in...
BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency
New biosimilar Type 2a meeting will facilitate faster development, stakeholders said, but one representative also warned that the inspection backlog must be eliminated in order for the US FDA to meet the new user fee program commitments.
BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency
New biosimilar Type 2a meeting will facilitate faster development, stakeholders said, but one representative also warned that the inspection backlog must be eliminated in order for the US FDA to meet the new user fee program commitments.
Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed
The US FDA’s capacity planning formula indicates a smaller biosimilar program than a year ago, but says supplement, meeting and other work continue to increase.